First Application of Ketogenic Diet on a Child With Intractable Epilepsy in Ghana

Dezhi Cao1, Eben Badoe2, Yanwei Zhu1

  • 1Shenzhen Children's Hospital, Shenzhen, Guangdong, China.

Insights

Ketogenic diet therapy offers a low-cost, effective treatment for intractable epilepsy in children. This study successfully used the ketogenic diet to control seizures in a Ghanaian infant, showing promise for wider application in Africa.

Area of Science:

  • Neurology
  • Pediatrics
  • Nutritional Science

Background:

  • Epilepsy prevalence is higher in sub-Saharan Africa, with limited effective treatments for intractable cases.
  • Epilepsy surgery is often inaccessible due to high costs and specialized skill requirements.
  • Intractable epilepsy significantly impacts child development, necessitating accessible therapeutic options.

Purpose of the Study:

  • To evaluate the efficacy of ketogenic diet therapy as a low-cost, accessible treatment for intractable epilepsy in children.
  • To document the successful application of ketogenic diet in a pediatric case in Ghana, West Africa.

Main Methods:

  • A 10-month-old female infant with intractable epilepsy (unknown etiology) was treated.
  • The patient had failed treatment with over three antiepileptic drugs.
  • Ketogenic diet therapy was initiated due to its low cost and simple procedure.

Main Results:

  • Complete seizure control was achieved within two weeks of initiating ketogenic diet therapy.
  • Significant improvement in the patient's mental condition was observed post-therapy.
  • The case demonstrated the feasibility and effectiveness of ketogenic diet in this context.

Conclusions:

  • Ketogenic diet therapy is a viable and effective treatment for intractable epilepsy in children in resource-limited settings.
  • This case represents the first report of ketogenic diet application for intractable epilepsy in West Africa.
  • Further development and implementation of ketogenic diet therapy in Africa are warranted.

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.5K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
867
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.5K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
293
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
1.6K